Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lise, M.
Right arrow Articles by Gignoux, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lise, M.
Right arrow Articles by Gignoux, M.

Annals of Surgical Oncology, Vol 2, Issue 6 495-501, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapy

M. Lise, D. Nitti, A. Marchet, T. Sahmoud, N. Duez, A. Fornasiero, J. G. dos Santos, R. Labianca, P. Lasser and M. Gignoux
Istituto di Clinica Chirurgica II, Universita di Padova, Padua, Italy.

BACKGROUND: The high incidence of locoregional recurrences and distant metastases after curative surgery for gastric cancer calls for improved locoregional control and systemic adjuvant treatment. METHODS: In a randomized clinical trial on adjuvant FAM2 chemotherapy, quality of surgery was evaluated by comparing surgical and pathology data. Univariate and multivariate analysis was made to evaluate the effect of prognostic factors on survival and time of recurrence in relation to patients, tumor, and therapy. RESULTS: Of 314 patients randomized from 28 European institutions, 159 comprised the control and 155 the FAM2 group. After a median follow-up of 80 months, no statistically significant difference was found between survivals. However, for recurrence time, treated patients had a significant advantage over controls (p = 0.02). At univariate analysis, statistically significant differences in survival and time to progression emerged for T, N, disease stage and "adequacy" of surgery. The multivariate analysis retained preoperative Hb level, T, N, and "adequacy" of surgery for time of survival; and T, N, "adequacy" of surgery and adjuvant chemotherapy for recurrence time. CONCLUSIONS: Disease stage is the most important prognostic factor. "Adequate" surgery has an important effect. Adjuvant FAM2 delayed time of recurrence, but did not influence overall survival.


This article has been cited by other articles:


Home page
 JCOHome page
A. Ohtsu, S. Yoshida, and N. Saijo
Disparities in Gastric Cancer Chemotherapy Between the East and West
J. Clin. Oncol., May 10, 2006; 24(14): 2188 - 2196.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Nitti, J. Wils, J. G. Dos Santos, G. Fountzilas, P. F. Conte, C. Sava, A. Tres, R. C. Coombes, D. Crivellari, A. Marchet, et al.
Randomized phase III trials of adjuvant FAMTX or FEMTX compared with surgery alone in resected gastric cancer. A combined analysis of the EORTC GI Group and the ICCG
Ann. Onc., February 1, 2006; 17(2): 262 - 269.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. Lim, M. Michael, G. B. Mann, and T. Leong
Adjuvant Therapy in Gastric Cancer
J. Clin. Oncol., September 1, 2005; 23(25): 6220 - 6232.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Society of Surgical Oncology.